Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

14:20
09/20/17
09/20
14:20
09/20/17
14:20

Alnylam price target raised to $128 from $101 at JMP Securities

JMP Securities analyst Michael King, Jr. raised his price target on Alnylam to $128 from $101 after the company reported that its Apollo trial of patisiran hit its primary and all of its secondary endpoints. Not only did the trial show that patisiran can reverse disease progression, the drug's safety profile is "very encouraging," giving it the potential to be a "best-in-class treatment," said the analyst, who keeps an Outperform rating on the stock.

  • 20

    Sep

ALNY Alnylam
$75.04

-0.96 (-1.26%)

09/20/17
JEFF
09/20/17
NO CHANGE
Target $102
JEFF
Buy
Jefferies says Alnylam patisiran results a 'best-case scenario'
Jefferies analyst Maury Raycroft views Alnylam's (ALNY) topline results from the Apollo trial of patisiran as "highly positive" and a "best-case scenario" from a competitive perspective. The lack of any notable safety signal and benefit on secondary endpoints further distinguishes this "as a clear win" and should help the company's negotiations with payers, he tells investors. Patisiran appears to have a superior safety profile to Ionis' (IONS) inotersen, added Raycroft, who has a Buy rating and $102 price target on Alnylam shares.
09/20/17
PIPR
09/20/17
NO CHANGE
Target $116
PIPR
Overweight
Piper ups Alnylam target to $116 on positive patisiran data
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $116 from $110 after the company reported positive Phase III Apollo data on patisiran in 225 hereditary ATTR amyloidosis with olyneuropathy patients. Importantly, patisiran demonstrated a clean safety profile that differentiates from Ionis Pharmaceuticals' (IONS) inotersen, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Alnylam. The stock in morning trading is up 41%, or $30.93, to $105.97. Ionis is down 8% to $54.10.
09/20/17
EVER
09/20/17
NO CHANGE
Target $65
EVER
Outperform
Ionis story still about SMA launch, Huntington's data, says Evercore ISI
Evercore ISI Joshua Schimmer said he wouldn't be surprised to see Ionis (IONS) shares fall 5%-10% after competitor Alnylam (ALNY) reported positive results from the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. However, he believes the Ionis story continues to be about the Spinraza launch in SMA with partner Biogen (BIIB) and its Huntington's data later this year. He keeps an Outperform rating and $65 price target on Ionis shares, which are down nearly 9% in early trading to $53.92.
09/20/17
PIPR
09/20/17
NO CHANGE
Target $110
PIPR
Overweight
Alnylam study 'hits with clean safety,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Alnylam Pharmaceuticals (ALNY) with a $110 price target saying the Apollo study hit "with clean safety." The analyst believes the clean safety profile differentiates Alnylam's patisiran from competitor Ionis Pharmaceuticals' (IONS) inotersen. Alnylam retains full rights to patisiran in the U.S. and Europe and is partnered with Sanofi for rest of world, Tenthoff tells investors in a research note. Alnylam shares are up 21% to $90.51 in premarket trading while Ionis is down 8% to $54.50.

TODAY'S FREE FLY STORIES

CAR

Avis Budget

$39.94

-0.08 (-0.20%)

15:34
02/21/18
02/21
15:34
02/21/18
15:34
Options
Avis Budget options imply 12.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VBTX

Veritex

$27.59

-0.48 (-1.71%)

15:33
02/21/18
02/21
15:33
02/21/18
15:33
Conference/Events
Veritex management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 24

    Sep

VBTX

Veritex

$27.59

-0.48 (-1.71%)

15:29
02/21/18
02/21
15:29
02/21/18
15:29
Conference/Events
Veritex management to meet with Stephens »

Meeting to be held in St.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 27

    Feb

  • 24

    Sep

OMER

Omeros

$11.37

0.36 (3.27%)

15:29
02/21/18
02/21
15:29
02/21/18
15:29
Periodicals
Omeros has 'plunging' Omidria sales, 'shaky' balance sheet, Feuerstein says »

Adam Feuerstein of STAT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TI

Telecom Italia

$8.84

-0.11 (-1.23%)

15:27
02/21/18
02/21
15:27
02/21/18
15:27
Hot Stocks
Telecom Italia says not involved in any anticompetitive behavior »

Regarding today's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KS

KapStone

$34.69

0.14 (0.41%)

15:24
02/21/18
02/21
15:24
02/21/18
15:24
Conference/Events
KapStone management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCBK

TriCo Bancshares

$37.24

-0.76 (-2.00%)

15:19
02/21/18
02/21
15:19
02/21/18
15:19
Conference/Events
TriCo Bancshares management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

AAOI

Applied Optoelectronics

$33.33

1.34 (4.19%)

15:19
02/21/18
02/21
15:19
02/21/18
15:19
Options
Applied Optoelectronics options imply 22.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 13

    Mar

  • 29

    Mar

$NSD

NASDAQ Market Internals

15:17
02/21/18
02/21
15:17
02/21/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$272.87

1.47 (0.54%)

, SPX

S&P 500

15:16
02/21/18
02/21
15:16
02/21/18
15:16
Technical Analysis
Technical Take: S&P 500 retests lows of the day »

At time of writing the…

SPY

SPDR S&P 500 ETF Trust

$272.87

1.47 (0.54%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$272.87

1.47 (0.54%)

, SPX

S&P 500

15:16
02/21/18
02/21
15:16
02/21/18
15:16
Technical Analysis
Technical Take: S&P 500 retests lows of the day »

At time of writing the…

SPY

SPDR S&P 500 ETF Trust

$272.87

1.47 (0.54%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
02/21/18
02/21
15:16
02/21/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABG

Asbury Automotive

$68.25

0.3 (0.44%)

15:15
02/21/18
02/21
15:15
02/21/18
15:15
Conference/Events
Asbury Automotive management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
02/21/18
02/21
15:15
02/21/18
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

WFC

Wells Fargo

$60.35

0.4 (0.67%)

15:10
02/21/18
02/21
15:10
02/21/18
15:10
Options
Notable call write in Wells Fargo »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 06

    Mar

  • 07

    Mar

  • 15

    Mar

  • 30

    May

AZN

AstraZeneca

$34.09

0.45 (1.34%)

15:08
02/21/18
02/21
15:08
02/21/18
15:08
Hot Stocks
AstraZeneca announces renewed recommendation, availability of FLUMIST vaccine »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 23

    Apr

P

Pandora

$4.96

-0.375 (-7.04%)

15:04
02/21/18
02/21
15:04
02/21/18
15:04
Options
Pandora options imply 26.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

  • 26

    Feb

  • 05

    Mar

BA

Boeing

$358.70

5.35 (1.51%)

, EADSY

Airbus

$29.67

0.08 (0.27%)

15:03
02/21/18
02/21
15:03
02/21/18
15:03
Periodicals
Boeing displaces Airbus at Hawaiian, Leeham News and Comment says »

Boeing (BA) has displaced…

BA

Boeing

$358.70

5.35 (1.51%)

EADSY

Airbus

$29.67

0.08 (0.27%)

HA

Hawaiian Holdings

$37.35

-1.3 (-3.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 30

    May

NFLX

Netflix

$278.55

0.03 (0.01%)

15:03
02/21/18
02/21
15:03
02/21/18
15:03
Periodicals
Netflix and indie film makers Duplass Brothers in deal, Variety reports »

Variety reported earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 20

    Mar

MBT

Mobile TeleSystems

$12.66

0.49 (4.03%)

15:00
02/21/18
02/21
15:00
02/21/18
15:00
Options
Call buyers in Mobile TeleSystems as shares reach 52-week highs »

Call buyers in Mobile…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPZ

Domino's Pizza

$223.26

1.77 (0.80%)

, QSR

Restaurant Brands

$59.54

0.31 (0.52%)

14:50
02/21/18
02/21
14:50
02/21/18
14:50
Periodicals
Restaurant Brands deal for Domino's 'likely,' 680 NEWS Toronto reporter says »

Richard Southern of 680…

DPZ

Domino's Pizza

$223.26

1.77 (0.80%)

QSR

Restaurant Brands

$59.54

0.31 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 07

    Mar

  • 30

    May

ROKU

Roku

$51.18

3.05 (6.34%)

14:49
02/21/18
02/21
14:49
02/21/18
14:49
Options
Roku Inc (Class A Stock) options imply 26.4% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 21

    Mar

CGG

CGG SA

$3.97

-0.24 (-5.70%)

14:45
02/21/18
02/21
14:45
02/21/18
14:45
Hot Stocks
Breaking Hot Stocks news story on CGG SA 

CGG SA trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$117.30

2.59 (2.26%)

14:45
02/21/18
02/21
14:45
02/21/18
14:45
Recommendations
JPMorgan analyst commentary  »

JPMorgan price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 25

    Feb

  • 27

    Feb

  • 07

    Mar

  • 13

    Mar

  • 13

    Apr

  • 30

    May

  • 14

    Jul

  • 12

    Oct

NGVT

Ingevity

$77.41

5.14 (7.11%)

14:42
02/21/18
02/21
14:42
02/21/18
14:42
Hot Stocks
Ingevity sees $1.5B in revenue, adjusted EBITDA $500M in 2022 »

Comments are from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.